Antihyperlipidemic and antidiabetic effects of umbelliferone in streptozotocin diabetic rats.
The aim of the study was to evaluate blood glucose and lipid lowering effects of Umbelliferone (UMB) in streptozotocin (STZ) diabetic rats. Male albino Wistar rats (180 to 200 g) were induced diabetes by administration of STZ (40 mg/kg) intraperitonially. Normal and diabetic rats were treated with UMB in 10 percent dimethyl sulfoxide (DMSO) for 45 days. Diabetic rats had increased plasma glucose and decreased insulin, total proteins (TP), and albumin in addition to decreased food intake and body weight. Elevation in total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), triglycerides (TG), free fatty acids (FFA), and phospholipids (PL), and reduction in high density lipoprotein cholesterol (HDL-C) in the plasma were observed. Liver and kidney tissues of diabetic rats had elevation in the levels of TC, TG, FFA, and PL. Treatment with UMB decreased plasma glucose and increased insulin, TP, and albumin apart from food intake and body weight. In UMB-treated diabetic rats, plasma and tissue TC, TG, PL and FFA, and plasma LDL-C, VLDL-C, and HDL-C reversed to near normal. Thus, reduction of blood glucose and lipid profiles indicates that UMB has antidiabetic and antihyperlipidemic effects in diabetic rats.
Ramesh
B
B
Department of Biochemistry, Faculty of Science, Annamalai University, Annamalainagar, Tamilnadu, India.
Pugalendi
K V
KV
D000418:Albumins / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005247:Feeding Behavior; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008956:Models, Chemical; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism; D014468:Umbelliferones / Q000627:therapeutic use*
D000418:Albumins; D001786:Blood Glucose; D008076:Cholesterol, HDL; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D014280:Triglycerides; D014468:Umbelliferones; D013311:Streptozocin; C031477:7-hydroxycoumarin; D002784:Cholesterol